Good day, and welcome to the Biote Fourth Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions]. I would now like to turn the conference over ...

Revenue: $49.8 million for Q4 2024, up 9% year-over-year. Procedure Revenue Growth: Increased 5%, impacted by transition to new software and training focus. Dietary Supplement Revenue: Increased 10.2% ...

Peterson stated, "we reiterate our fiscal 2025 revenue guidance of above $190 million and our fiscal 2025 adjusted EBITDA guidance of above $50 million." Management continues to expect mid-teens ...

IRVING, Texas--(BUSINESS WIRE)-- Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today ...

IRVING, Texas, August 06, 2025--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today ...

Biote Corp (BTMD) reported its Q1 2025 earnings, surpassing Wall Street expectations with an EPS of $0.37, compared to the forecast of $0.14. The company’s revenue reached $49 million, exceeding the ...

biote Corp. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome to the Biote First Quarter 2024 Earnings ...

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for ...